



Please find our Research on Bloomberg BRYG <GO>)

13th September 2016

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18325.07	+1.32%	+5.17%
S&P 500	2159.04	+1.47%	+5.63%
Nasdaq	5211.89	+1.68%	+4.08%
Nikkei	16729.04	+0.34%	-12.40%
Stoxx 600	342.232	-0.95%	-6.45%
CAC 40	4439.8	-1.15%	-4.25%
Oil /Gold			
Crude WTI	46.29	+0.89%	+24.44%
Gold (once)	1324.57	-0.70%	+24.68%
Currencies/Rates			
EUR/USD	1.122	+0.08%	+3.29%
EUR/CHF	1.0926	-0.22%	+0.48%
German 10 years	-0.023	-54.99%	-103.63%
French 10 years	0.27	+15.94%	-72.49%
Euribor	-	+-%	+-%

Economic releases :

Date

13th-Sept GB - CPI Aug. (0.7%E)

- GB Core CPI (1.4% E y/y)
- DE CPI (0.4% E y/y)
- DE ZEW current situation Sep. (56E)
- EUZ ZEW Eco Sentiment Sep.

Upcoming BG events :

Date	
13th-Sept	Thematic Breakfast with ARCEP
14th-Sept	SAINT GOBAIN (BG Luxembourg roadshow)
22nd-Sept	Thematic Lunch with HC specialist
30th-Sept	Thematic Breakfast with Vimpelcom
28th-Oct	IMERYS (Paris roadshow)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference

Recent reports :

Date 9th-Sept	ENGIE The twelve labours of Engie
7th-Sept	FRESENIUS : ¡Salud!
6th-Sept	WIRECARD Ready to reconnect with the fundamentals
•	AMS Catching the ball when it bounces - all a question of timing
26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth

List of our Reco & Fair Value : Please click here to download



BG's Wake Up Call

ATOS

BUY, Fair Value EUR102 vs. EUR93 (+13%)

Acquisition of Anthelio Healthcare Solutions in the US

We reiterate our Buy rating and increase our DCF-derived fair value to EUR102 from EUR93 on updated assumptions for medium-term Ifl sales growth (3% vs. 2% = +EUR5/share), WCR (-6% of sales vs. -3% = +EUR4) and fx (-EUR1), and our increased EPS ests. (+EUR1). Yesterday evening, Atos announced the acquisition of Anthelio for USD275m in cash or an 8.5x 2017 post-synergies EV/EBIT multiple. This acquisition, which we consider as 2% accretive to our adj. EPS ests. for 2017-18, allows Atos to enlarge its customer base in Healthcare in the US.

CAST

NEUTRAL, Fair Value EUR3.6 (+3%)

H1 2016 results below our expectations, but FY16 guidance reiterated

Yesterday evening, Cast reported H1 2016 results below our expectations, but confirmed its FY 16 target to post revenue growth above 10% while staying profitable. The deal flow remains promising and the large contract postponed in June with a US bank is still on the cards. We expect no significant share price reaction on the back of these numbers.

KERING

BUY, Fair Value EUR185 vs. EUR175 (+6%)

Gucci momentum should remain positive short term

After a strong performance by Kering Group in Q2, particularly at Gucci brand, we remain very confident for H2 and 2017, both for Gucci brand and Kering Group. Consequently, we revise up our 2016 and 2017 expectations by 3% and we upgrade our Fair Value from EUR175 to EUR185 and remain at Buy on the stock, as we anticipate sales momentum remaining positive in coming quarters.

LUXOTTICA

NEUTRAL, Fair Value EUR54 (+27%)

Recent trends confirm our scenario for H2 16

In Q2 Luxottica's own initiatives (MAP policy at Ray-Ban, direct go-to-market approach in mainland China, etc.) proved to be more harmful than expected, this headwind being exacerbated by a challenging macro environment. Although the Group's actions will still weigh in H2, we understand that the end of the summer showed that some drivers could help LUX to post a slight and sequential acceleration throughout H2 (+3%e vs. +1.6% in H1) to match FY guidance.

INSURANCE

Pretty satisfactory "Rendez-Vous de Septembre"

It should be a pretty satisfactory "Rendez-Vous de Septembre" this year, driven by a slightly better price environment and short/mid-term business opportunities (Solvency II, big data, cyber...). In the current environment, reinsurers deserve their premium to primary insurers, even if the current 15-20% premium seem a little high to us. So look for entry points!


Return to front page

BUY

Atos Price EUR90.27

TMT

Bloomberg Reuters 12-month High / L Market Cap (EUR) Ev (BG Estimates) Avg. 6m daily volu 3y EPS CAGR	(EUR)			ATO FP ATOS.PA 4 / 62.7 9,457 8,768 309.7 14.9%
	1 M	3 M	6 M 31	/12/15
Absolute perf. Softw.& Comp.	1.3% 1.3%	14.2% 10.6%	32.2% 11.3%	16.6% 6.0%
DJ Stoxx 600	-1.1%	2.8%	0.0%	-6.4%
YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	10,686	11,803	12,341	12,634
% change		10.5%	4.6%	2.4%
EBITDA	1,334	1,545	1,722	1,809
EBIT	589.0	834.0	922.0	1,010
% change		41.6%	10.6%	9.5%
Net income	609.0	736.0	870.0	947.0
% change		20.9%	18.2%	8.9%
	2015	2016e	2017e	2018e
Operating margin	8.6	9.3	10.1	10.5
Net margin	4.0	5.1	5.6	6.2
ROE	9.9	13.3	13.4	13.3
ROCE	22.9	25.7	41.3	46.8
Gearing	-14.0	-16.0	-48.0	-57.0
(€)	2015	2016e	2017e	2018e
EPS	5.83	6.95	8.18	8.84
% change	-	19.2%	17.7%	8.1%
P/E	15.5x	13.0x	11.0x	10.2x
FCF yield (%)	4.2%	5.6%	6.7%	8.7%
Dividends (€)	0.90	1.10	1.40	1.55
Div yield (%)	1.0%	1.2%	1.6%	1.7%
EV/Sales	0.8x	0.7x	0.6x	0.5x
EV/EBITDA	6.6x	5.7x	4.1x	3.5x
EV/EBIT	9.7x	8.0x	5.7x	4.8x



Acquisition of Anthelio Healthcare Solutions in the US Fair Value EUR102 vs. EUR93 (+13%)

We reiterate our Buy rating and increase our DCF-derived fair value to EUR102 from EUR93 on updated assumptions for medium-term IfI sales growth (3% vs. 2% = +EUR5/share), WCR (-6% of sales vs. -3% = +EUR4) and fx (-EUR1), and our increased EPS ests. (+EUR1). Yesterday evening, Atos announced the acquisition of Anthelio for USD275m in cash or an 8.5x 2017 post-synergies EV/EBIT multiple. This acquisition, which we consider as 2% accretive to our adj. EPS ests. for 2017-18, allows Atos to enlarge its customer base in Healthcare in the US.

ANALYSIS

- **Strategic rationale of the deal**. Atos signed an agreement to acquire Anthelio Healthcare Solutions, which is the largest independent provider of healthcare technology solutions in North America, for an enterprise value of USD275m, or an 8.5x EV/EBIT multiple, post-synergies, for 2017. This deal, to be fully financed by cash and expected to close late September, strengthens Atos' presence in Healthcare in the US with est. USD0.4bn revenue in Healthcare IT and est. USD2.5bn revenues in North America. Founded in 1999 in Dallas (Texas), Anthelio generates c.USD200m revenues (growing at 8%) with 1,700 staff (1,300 in the US and 400 in India), essentially in Managed Services (IT management, BPO services such as medical coding, revenue cycle management, patient financial services, clinical documentation, cancer registry services, electronic medical records). Its largest customer is McLaren Health Care, which had a 26% stake in Anthelio and signs a partnership with Atos through a 5-year renewed outsourcing contract.
- A bit of synergies ahead. We understand that this year Anthelio will generate an operating margin around 11-12% for revenues at c. USD200m. Based on the 8.5x post-synergies EV/EBIT multiple expected for 2017, we estimate 2017 EBIT around USD32m. These synergies are expected to be primarily on revenues. Based on a 2017 revenue assumption above USD220m taking into account at least 8% growth we consider Anthelio's operating margin would reach 14%, notwithstanding the assumption that the remaining synergies will materialise in 2018. In total, we estimate the synergies between Anthelio and Atos will be around USD10m, or c. 4% of sales, by end 2018.
- We estimate adj. EPS accretion at 2% by 2018. Based on an operating margin of 11% for 2016, 14% for 2017 and 16% for 2018, synergies around USD10m by 2018 and a first consolidation date at 1st October 2016, we estimate Anthelio will be accretive to EPS by 1% for 2016 and 2% for 2017-18. We calculate that Atos will enhance its non-IFRS operating margin by 0.1ppt from 2017 onwards. We consider the deal is too small to have an impact on free cash flow, which explains why Atos has not changed FY16 company guidance regarding free cash flow above EUR550m. However, we understand Anthelio generates a free cash flow around 50% of EBIT.
- **Capital Markets Day in sight**. While Anthelio has a negligible impact to our DCF-derived fair value (+EUR1), we increase it to EUR102 lies in the run-up the next Capital Markets Day scheduled on 8th November. We consider that, while organic growth tends to accelerate on the back of some acceleration at Worldline, solid growth in Big Data & Cybersecurity and the turnaround in Systems Integration thanks to the focus made on digital transformation, management will be able to achieve at least 2-3% lfl sales growth and a double-digit operating margin by 2020.

VALUATION

- Atos' shares are trading at est. 8.0x 2016 and 5.7x 2017 EV/EBIT multiples.
- Net cash position on 30th June 2016 was EUR412.3m (net gearing: -10%).

NEXT CATALYSTS

Q3 2016 sales on 20th October before markets open.

Analyst :



Gregory Ramirez 33(0) 1 56 68 75 91 gramirez@bryangarnier.com Sector Team : Richard-Maxime Beaudoux Thomas Coudry Dorian Terral

Return to front page

NEUTRAL

Cast Price EUR3.50

TMT

Bloomberg Reuters 12-month High / Lo Market Cap (EUR) Ev (BG Estimates) (Avg. 6m daily volur 3y EPS CAGR	EUR)		:	CAS.PA CAS FP 3.6 / 3.0 57 41 7.40 ns
	1 M	3 M	6 M 31	/12/15
Absolute perf.	0.6%	1.4%	6.1%	15.9%
Softw.& Comp. SVS	1.3%	10.6%	11.3%	6.0%
DJ Stoxx 600	-1.1%	2.8%	0.0%	-6.4%
YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	36.3	40.1	45.3	50.7
% change		10.3%	13.0%	12.0%
EBITDA	1.3	3.4	4.6	6.3
EBIT	0.8	0.6	1.9	3.7
% change		-14.5%		94.9%
Net income	0.1	0.6	1.5	2.8
% change			147.6%	87.4%
	2015	2016e	2017e	2018e
Operating margin	2.4	1.9	4.5	7.6
Net margin	0.1	1.4	3.2	5.4
ROE	0.4	4.2	9.6	15.3
ROCE	139.6	-27.3	-42.2	-56.9
Gearing	-99.3	-114.3	-121.7	-125.6
(EUR)	2015	2016e	2017e	2018e
EPS	0.00	0.04	0.10	0.18
% change	-		147.8%	87.4%
P/E	NS	90.4x	36.5x	19.5x
FCF yield (%)	0.8%	4.9%	5.2%	7.5%
Dividends (EUR)	0.00	0.00	0.00	0.00
Div yield (%)	NM	NM	NM	NM
EV/Sales	1.2x	1.0x	0.8x	0.7x
EV/EBITDA	33.2x	11.9x	8.3x	5.4x
EV/EBIT	50.8x	54.7x	18.9x	8.9x



H1 2016 results below our expectations, but FY16 guidance reiterated

Fair Value EUR3.6 (+3%)

Yesterday evening, Cast reported H1 2016 results below our expectations, but confirmed its FY 16 target to post revenue growth above 10% while staying profitable. The deal flow remains promising and the large contract postponed in June with a US bank is still on the cards. We expect no significant share price reaction on the back of these numbers.

ANALYSIS

H1 2016 results below our expectations but in line with management's anticipations. For H1 2016, Cast reported sales down 1.6% to EUR14.6m (-0.9% lfl), an operating loss of EUR3.9m (vs. a EUR2.4m operating loss in H1 2015) below than our EUR2.9m forecast, and a net loss of EUR4.1m (vs. a net loss of EUR2.5m in H1 2015). These results are in line with the management's anticipation that the operating loss would deteriorate due to the slippage of two large transactions in Q2. Operating expenses were up 7.6% to EUR18.5m, which is a deceleration compared to the +14% reported for 2015 in H1 and H2 due to lower sales commissions due to the revenue miss in Q2.

Net cash increase. During the period, free cash improved by EUR1.3m, leading to a net cash position of EUR14.3m on 30th June 2016. This increase stemmed from working capital improvement (EUR4m) - primarily on accounts receivable (EUR5m), while the operating cash flow was EUR0.3m, capex were EUR0.3m and Cast bought back EUR0.1m shares.

FY16 guidance reiterated. Cast reiterates FY16 guidance, i.e. sales up above 10% and a positive operating profit, based on the reiteration of a strong sales pipeline and confidence that the large deal which slipped with a US bank in June will be signed in the coming weeks or months. Investments planned for this year are a bit behind schedule due to delayed hiring. While management remains comfortable with a EUR40m revenue scenario, the operating profit would be, as mentioned previously, close to the level of 2015 (EUR0.8m), based on our scenario of an opex increase of 10% (o/w +14% for H2 2016).

Update on partnerships. Management considers the alliance with BCG is promising, but still slow to ramp-up revenues as no shortening of the sales cycle has been noticed so far. With McKinsey, Cast is essentially on 'tactical' deals with a small size. With IT Services companies, the most buoyant revenue prospects are with Cognizant, Accenture and IBM.

VALUATION

- Cast's shares are trading at est. 54.7x 2016 and 18.9x 2017 EV/EBIT multiples.
- Net cash position on 30th June 2016 was EUR14.3m.

NEXT CATALYSTS

Q3 2016 sales on 31st October after markets close.

Click here to download



Analyst : **Gregory Ramirez** 33(0) 1 56 68 75 91 gramirez@bryangarnier.com

Sector Team : **Richard-Maxime Beaudoux** Thomas Coudry Dorian Terral

Luxury & Consumer Goods

Kering Price EUR174.90

Bloomberg Reuters 12-month High / L Market Cap (EURn Ev (BG Estimates) Avg. 6m daily volu 3y EPS CAGR			PP FP PRTP.PA 22,084 24,884 239.2 13.7%	
	1 M	3 M	6 M 31	/12/15
Absolute perf.	-1.1%	15.5%	5.2%	10.7%
Pers & H/H Gds	-2.8%	2.1%	2.0%	1.2%
DJ Stoxx 600	-1.1%	2.8%	0.0%	-6.4%
YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	11,584	12,060	12,800	13,450
% change		4.1%	6.1%	5.1%
EBITDA	2,056	2,225	2,490	2,695
EBIT	1,646	1,805	2,050	2,255
% change		9.7%	13.6%	10.0%
Net income	1,017	1,138	1,343	1,519
% change		11.9%	18.0%	13.1%
	2015	2016e	2017e	2018e
Operating margin	14.2	15.0	16.0	16.8
Net margin	8.8	9.4	10.5	11.3
ROE	8.7	8.8	9.8	10.7
ROCE	5.8	6.3	7.1	7.8
Gearing	37.7	27.1	21.9	21.2
(EUR)	2015	2016e	2017e	2018e
EPS	8.05	9.00	10.54	11.83
% change	-	11.9%	17.1%	12.2%
P/E	21.7x	19.4x	16.6x	14.8x
FCF yield (%)	1.3%	2.7%	3.8%	4.5%
Dividends (EUR)	4.00	4.30	4.70	5.20
Div yield (%)	2.3%	2.5%	2.7%	3.0%
EV/Sales	2.2x	2.1x	1.9x	1.8x
EV/EBITDA	12.6x	11.2x	9.8x	9.0x
EV/EBIT	15.7x	13.8x	11.9x	10.8x



Return to front page

BUY

Gucci momentum should remain positive short term

Fair Value EUR185 vs. EUR175 (+6%)

After a strong performance by Kering Group in Q2, particularly at Gucci brand, we remain very confident for H2 and 2017, both for Gucci brand and Kering Group. Consequently, we revise up our 2016 and 2017 expectations by 3% and we upgrade our Fair Value from EUR175 to EUR185 and remain at Buy on the stock, as we anticipate sales momentum remaining positive in coming quarters.

ANALYSIS

After the very encouraging H1 performance (+5.2% for Luxury division in Q2 following +2.7% in Q1), particularly for Gucci brand (+7.4% in Q2 despite a demanding comparison basis after +3.1% in Q1), we remain very confident on H2 prospects. We are convinced that Gucci brand is currently one of the most successful luxury brand. Alessandro Michele collections are still enjoying considerable success. Shoes and ready-to-wear have already convinced consumers since Q1 and even more in Q2. This positive trend is likely to continue in Q3 and we think even in Europe as was the case in Q2 (+20%), while all others luxury brands were hit by reduced tourists flows. Furthermore, leather goods are beginning to gain market share too, and the brand is launching fall a new leather goods line this: the *Marmont* with leather matelassé shoulder bag sold at EUR1,400. The segment around EUR1,500 is the most dynamic leather goods segment after small leather goods. It is worth noting that this line is sold with the **GG** logo which highlights the comeback of logo lines, in line with Alesandro Michele's view. According to him, logo is part of the brand's DNA. The former brand artistic director, Frida Giannini, was less focused on the logo. Furthermore, it is worth noting that the comps in Q3 are far less demanding than in Q2, as Gucci's Q3 2015 sales were down 0.4% (+4.6% in Q2 2015).

- **Even if Bottega Veneta is the only sore point for the group with sales down 9.1% in H1**, particularly affected by high exposure to Asian tourists (70% of brand's sales, of which 15% generated in HK/Macau), **YSL** remained very well oriented thanks to 24% revenues growth with strong momentum in all geographical areas and in all segments. BV will also benefit from an easier comparison basis (in Q3 2015, sales were up 4% vs +9% in Q2 and Q4 will be even easier with a 4% decline). Furthermore, **Puma** is regaining strong momentum with sales up 10.6% in H1 of which +13.2% in Q2, partly thanks to the EURO football tournement in France in June. In line with company guidance, FY 2016 sales should be up HSD (+9.5% in our model).
- For the whole group, we anticipate 5.5% organic sales growth for 2016 vs +5% previously implying +5.2% in Q3 and +4.9% in Q4. For Kering Luxury alone, sales should grow 4.6% organically, of which +6% for Gucci brand (+5% previously). In 2017, we expect sales to increase 6% of which +5.5% for Luxury division and +6% for Gucci. H1 EBIT margin was up 20bp to 14.2% of which +80bp for Gucci. For FY 2016, we expect profitability to gain 70bp to 14.9% (+50bp previously), implying +100bp in H2 alone. For 2017, profitability improvement is expected to continue and we anticipate a 100bp gain, mainly from Gucci (+130bp to 28.4%). Gucci management has ambition plans to improve brand profitability.

VALUATION

Kering's share price has been one of the best performers among luxury stocks over the last three months with a 15% increase while our luxury sample average is up 4%. Furthermore, Kering stock outperformed DJ Stoxx by 12% and is trading globally in line with sector average on 2016 EV/EBIT. Given our new earnings prospects, we upgrade our Fair Value from EUR175 to EUR185 and we reiterate our Buy recommendation as we are convinced that the group's sales momentum should remain quite positive in the following quarters, hence our positive view despite the recent strong share price rally.

NEXT CATALYSTS

Q3 sales are expected to be reported on October25th.

Click here to download




Analyst : Loïc Morvan 33(0) 1 70 36 57 24 Imorvan@bryangarnier.com Sector Team : Nikolaas Faes Antoine Parison Cédric Rossi Virginie Roumage

Luxury & Consumer Goods

Luxottica Price EUR42.41

Bloomberg Reuters 12-month High / Lu Market Cap (EUR) Ev (BG Estimates) Avg. 6m daily volu 3y EPS CAGR	(EUR)		65	LUX IM LUX.MI .6 / 42.3 20,522 21,286 884.3 10.0%
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	-4.5%	-7.3%	-16.2%	-29.8%
Consumer Gds	-2.6%	2.8%	2.2%	-2.2%
DJ Stoxx 600	-1.1%	2.8%	0.0%	-6.4%
YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	8,837	9,135	9,633	10,207
% change		3.4%	5.5%	6.0%
EBITDA	1,853	1,896	2,135	2,305
EBIT	1,376	1,388	1,600	1,738
% change		0.9%	15.2%	8.6%
Net income	804.1	826.7	977.6	1,072
% change		2.8%	18.3%	9.7%
	2015	2016e	2017e	2018e
Operating margin	15.6	15.2	16.6	17.0
Net margin	9.1	9.1	10.1	10.5
ROE	14.6	14.1	15.5	15.9
ROCE	12.0	12.0	13.9	15.3
Gearing	18.2	13.0	6.0	-2.7
(€)	2015	2016e	2017e	2018e
EPS	1.68	1.72	2.04	2.23
% change	-	2.7%	18.3%	9.7%
P/E	25.3x	24.6x	20.8x	19.0x
FCF yield (%)	3.6%	3.9%	5.0%	6.1%
Dividends (€)	0.89	1.00	1.10	1.22
		2.4%	2.6%	2.9%
Div yield (%)	2.1%	2.4%	2.070	2.7/0
Div yield (%) EV/Sales	2.1% 2.4x	2.4% 2.3x	2.0%	2.9% 2.0x
3				



Recent trends confirm our scenario for H2 16

Fair Value EUR54 (+27%)

In Q2 Luxottica's own initiatives (MAP policy at Ray-Ban, direct go-to-market approach in mainland China, etc.) proved to be more harmful than expected, this headwind being exacerbated by a challenging macro environment. Although the Group's actions will still weigh in H2, we understand that the end of the summer showed that some drivers could help LUX to post a slight and sequential acceleration throughout H2 (+3%e vs. +1.6% in H1) to match FY guidance. ANALYSIS

MAP policy at Ray-Ban in North America: too early to expect the tipping point in the short term. Overall, Ray-Ban grew at a low-single-digit rate, but the U.S sun business declined by ~5%e mainly due to the implementation of the "Minimum Advertised Price" policy, which had a direct impact on online sales (-50% in Q2). Given its recent implementation in July, the Group cannot communicate on a precise tipping point in the ST. Our forecast factors in the same negative impact as in Q2, as the weight of sun within the category mix should be lower throughout the remainder of the year (Rx remains buoyant).

North America: where the sun did not shine in Q2. Besides this necessary initiative at Ray-Ban, Oakley was affected by the complicated sport sunglass channel, as highlighted by the bankruptcy of a leading sporting goods retailer, Sports Authority (450 stores). Other brands such as Costa (Essilor) and Smith (Safilo) have also experienced these challenging market conditions, aggravated by a poor sun season. For H2, we expect a consolidation (U.S. Wholesale: flat vs. -1.7% FX-n) thanks to more favourable weather conditions over July and August and easier comparison bases, whilst Oakley will reorganize its Apparel-Footwear-Accessories business.

Macy's is closing 100 stores in 2017; not a major issue for Luxottica. There are two agreements currently under way between Macy's and LUX: (i) Sunglass Hut (signed in 2009) has approx. 670 locations within Macy's stores and (ii) LensCrafters (signed in November 2015) will open up to 500 stores by 2018, of which around 80 should be opened this year. Macy's has not specified the 100 branches that will close but, in our view, this decision should only marginally affect some SGH corners. On our estimates, SGH @ Macy's accounts for ~25% of SGH US and not more than 5% of total U.S. Retail. Moreover, the future CEO of Macy's next year Jeff Gennette repeated several times that key collaborations such as Apple, LC or SGH were key in Macy's plans to offer an expanded assortment and new customer experiences. As shown in the graph below, department stores and sunglass specialty channels continued to gain market share over 2014-16.

U.S. sunglass market: retail sales by channel (12m ending March):



Source: VisionWatch

VALUATION

Slight acceleration in H2: first step towards a gradual rerating? Whilst we expect these initiatives to remain a drag on performance, July and August seemed to confirm that LUX could benefit from three catalysts to achieve a slight acceleration over H2 (+3%e) and meet FY guidance (BG: +2.5%e vs. guidance of +2-3%): 1/ more favourable weather conditions across the U.S and Europe, 2/ the positive contribution from the opening of LensCrafters and Target Optical locations (+80 and +40 DOS respectively) and 3/ a less demanding comparison base (H2 15: +4.1% vs. +6.9% in H1).

NEXT CATALYSTS

Luxottica will release Q3 16 Sales on 24th October. Click here to download



Cédric Rossi 33(0) 1 70 36 57 25 crossi@bryangarnier.com Consumer Analyst Team: Nikolaas Faes/Virginie Roumage Loïc Morvan Antoine Parison

Return to front page

NEUTRAL

Return to front page

Sector View

Insurance

	1 M	3 M	6 M	31/12/15
Insurance	1.0%	0.5%	-7.5%	-17.4%
DJ Stoxx 600	-1.1%	2.8%	0.0%	-6.4%
*Stovy Sector Indices				

Companies covered

AEGON		NEUTRAL	EUR6
Last Price	EUR3.531	Market Cap.	EUR7,613m
ALLIANZ		BUY	EUR180
Last Price	EUR134.9	Market Cap.	EUR61,649m
AXA		BUY	EUR29
Last Price	EUR19.265	Market Cap.	EUR46,704m
CNP ASSURANC	ES	NEUTRAL	EUR15
Last Price	EUR14.465	Market Cap.	EUR9,932m
COFACE		NEUTRAL	EUR5.4
Last Price	EUR5.163	Market Cap.	EUR812m
EULER HERMES		BUY	EUR89
Last Price	EUR74.88	Market Cap.	EUR3,193m
HANNOVER RE		SELL	EUR110
Last Price	EUR92.6	Market Cap.	EUR11,167m
MUNICH RE		SELL	EUR185
Last Price	EUR164.15	Market Cap.	EUR26,437m
SCOR		BUY	EUR35
Last Price	EUR27.77	Market Cap.	EUR5,331m
SWISS RE		NEUTRAL	CHF100
Last Price	CHF85.75	Market Cap.	CHF30,876m
ZURICH INSURA	ANCE GROUP	NEUTRAL	CHF270
Last Price	CHF256.4	Market Cap.	CHF38,596m



Pretty satisfactory "Rendez-Vous de Septembre"

It should be a pretty satisfactory "Rendez-Vous de Septembre" this year, driven by a slightly better price environment and short/mid-term business opportunities (Solvency II, big data, cyber...). In the current environment, reinsurers deserve their premium to primary insurers, even if the current 15-20% premium seem a little high to us. So look for entry points!

ANALYSIS

- At the 60th anniversary of the Insurance/Reinsurance "Rendez-Vous de Septembre" in Monte Carlo, industry players continue to highlight the critical issue of low interest rates, which has put pressure on the overall underlying profitability, the necessity of renewed strong underwriting discipline and the overall positive impact of Solvency II.
- The "tiering" of the market, with 5-10 global players and 5-10 specialists capturing a growing part of the market, is now a reality and will continue to develop. These companies do not just offer capacity, they offer a broad range of knowledge (risk analysis, intra-group risk transfer pricing...) and services, so that reinsurance is not just a cost for ceding companies, but a way to optimise their own risk management and capital position. M&A activity is possible between Tier 2 and/or Tier 3 players as they need to adapt to the new environment, but Tier 1 players are not expected to be a part of it.
- Major players expect greater stability in prices and conditions at January 2017 renewals. Unsurprisingly, some loss-free segments are likely to see slight ongoing price erosion, but the sharply increased burden of attritional losses in 2016 (e.g. natcats in Germany or Canada) offer some price opportunities. The strong price pressure on US natcats has eased. Bottom line, the market has not turned hard, but the global picture is better than in previous years.
- In this moving environment, innovation and cycle management remain key. Reinsurers continue to express a growing interest for proportional business, as it enables them to be closer to primary markets' trends where the pricing environment is better. They are also aiming at developing their direct business relationship with corporates. Whatever the case, competition between players is tough.
- Opportunities also exit with new risk pools from the integration of data, analytics and technology that addresses the insurance protection gap. Cyber is still small as most players first need to build the learning curve, but the size of the market should triple by 2020 (USD8-10bn vs. USD3bn currently).
- Solvency II remains also a business opportunity: capital relief of course for companies that will find it hard to comply, but also more generally the fact that capital management has become the cornerstone of the management of all companies. The benefits of Solvency II for major reinsurers and primary insurers will gradually be seen in the next few years.
- Following four strong years, reinsurers' results are expected to return to more normalised levels in 2016, mainly driven by a higher natcat environment. But their capital positions are very strong and so are their ratings (AA- with stable outlook for the four reinsurers we cover), so capital returns are safe.

VALUATION

On average, reinsurers are currently trading at a 15%-20% premium to primary insurers, which seems a little high to us but not fully unjustified given the resilience of their business model and their favourable position as regards Solvency II. So look for attractive entry points!

Click here to download



Analyst : **Olivier Pauchaut** 33(0) 1 56 68 75 49 opauchaut@bryangarnier.com

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

	Stock ruting
BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a
	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to
	be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary
	event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key
	reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock
	will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.3%

NEUTRAL ratings 33.3%

SELL ratings 11.3%

Bryan Garnier Research Team

	J			
Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
ГМТ	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
		Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.con
Construction/ Infrastructures Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information	n Systems Manager	Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

ondon	Paris	New York	Munich	New Delhi
0 ,	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudential et de resolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 Geneva rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 Regulated by the FINMA



BRYAN, GARNIER & CO

Disclaimer:

10

Be 15 Lo Te Fa Au Fir

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB, United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris, France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investors which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....